AP NEWS
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

NewLink Genetics to Participate in Upcoming Investor and Medical Conferences

May 6, 2019

AMES, Iowa, May 06, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company will participate in the following investor and medical conferences:

Bank of America Merrill Lynch Global Health Care Conference 2019 on May 14-16 in Las Vegas

-- Management will present on Thursday, May 16 at 8:40 AM PT / 11:40 AM ET

Immuno-Oncology 2019 World Congress on May 23-24 in Barcelona, Spain

-- Poster presentation of Abstract #188 entitled, “A Phase 1 Clinical Trial of NLG802, a Prodrug of Indoximod with Enhanced Pharmacokinetic Properties”

A live webcast of the Bank of America Merrill Lynch Health Care Conference presentation will be available on the Company’s website at www.newlinkgenetics.com in the “Investors & Media” section under “ Events and Presentations.”

The poster to be presented at the Immuno-Oncology 2019 World Congress will be available on the Company’s website www.newlinkgenetics.com at 8:30 AM ET in the “Investors & Media” section under “ Posters & Publications.”

About NewLink Genetics Corporation

NewLink Genetics is a clinical stage biopharmaceutical company focusing on developing novel oncology product candidates to improve the lives of patients with cancer. NewLink Genetics’ IDO pathway inhibitors, indoximod and its prodrug, NLG802, are immuno-oncology drug candidates designed to harness multiple components of the immune system to combat cancer. NewLink Genetics’ drug candidate, NLG207 (formerly CRLX101), a nanoparticle formulation of topoisomerase 1 inhibitor, camptothecin, is under development to combat refractory malignancies. For more information, please visit www.NewLinkGenetics.com and follow us on Twitter @NLNKGenetics.

Investor & Media Contact:

Lisa MillerDirector of Investor RelationsNewLink Genetics515-598-2555 lmiller@linkp.com

Source: NewLink Genetics Corporation